HPTN COVID-19 Resource Center

Jump to:      Internal Resources & Guidance     External Resources     Media Coverage     Webinars & Events     Publications

The safety of our Network members and study participants is always our top priority. The HPTN Leadership Team has been monitoring updates and recommendations from the U.S. Centers for Disease Control and Prevention, the World Health Organization and numerous other health-based sources regarding the COVID-19 pandemic.

AS OF 29 MAY 2020, the original pauses to studies, screening, and enrollment that were put in place on March 16, 2020, are now lifted.

The following action steps still remain:

• No new studies will start at this time.

We continue to monitor the situation and may adjust our plans as needed. Thank you for your patience and understanding during this time of unprecedented change. 

Read more about the HPTN's involvement in the COVID-19 Prevention Network (CoVPN) at PreventCOVID.org

Internal Resources and Guidance

HPTN Letter to Network

COVID-19 Updates and Q&A Webinar: March 30, 2020 (webinar video)

Presented by Jessica Justman, MD, Senior Technical Director at ICAP

View slides

"Infectious Diseases Have Rules: Lessons From the Past for Facing COVID-19"
(Editorial by Myron Cohen and Wafaa El-Sadr)

External Resources and Guidance

GUIDANCE FOR RE-OPENING

• Resuming Operations at Sites (DAIDS) (21 May 2020)

General Guidance

• Avert: Resources for People Working in the HIV Sector

• CDC Strategies to Optimize the Supply of PPE and Equipment

• CDC: COVID-19-What people with HIV should know

• DAIDS COVID-19 Guidance

• DAIDS COVID-19 Monitoring Visits Guidance

• DAIDS Guidance on the Management of Clinical Trials during the COVID 19 (Coronavirus) pandemic 

• DAIDS Alternative Remote Informed Consent Process Memo (8 April 2020)

• DAIDS OCSO Monitoring Operations Branch: Extended Suspension of Monitoring Visits (6 April 2020)

• DAIDS Use of Alternate/Adjunct Venues During the COVID-19 Pandemic (8 May 2020)

• EMA Guidance on the Management of Clinical Trials during the COVID-19 (Coronavirus) Pandemic

• HANC COVID-19: Key Messages for HIV Community Advisory Groups/Community Members & Stakeholders

• WHO Risk Communication Package For Healthcare Facilities

• WHO Guidance on Getting Your Workplace Ready for COVID-19

• WHO Guidance for the Rational Use of Personal Protective Equipment (PPE) for Coronavirus Disease (COVID-19) (March 2020)

• WHO Q&A on COVID-19 and Masks

• UNICEF: U-Report COVID-19 Chatbot

• UNAIDS: What people living with HIV need to know about HIV and COVID-19 (Infographic)

• "Apart/Together: We Stand Strong Against COVID-19" - Song by Zimbabwean singer and poet Albert Nyathi (produced by ICAP)

• Guidelines for Network Lab Operations Recovery (1 May 2020)

• Phased Approach to Resumption of On-Site Monitoring Visits (11 May 2020)

Country-Specific

• Brazil: ANVISA Issues Updated Guidelines Related to COVID-19 and Clinical Trials (15 June 2020)

• Brazil: ANVISA Issues Notice for Clinical Trials Impacted by COVID-19 (23 March 2020)

• Brazil: ANVISA and CONEP Issue Updated Requirements Related to COVID-19 and Clinical Trials (5 May 2020)

• India: ICMR Issues Guidelines for EC Review during COVID-19 Pandemic

• Kenya PPB Issues Guidance for Clinical Trials Impacted by COVID-19 (Effective 20 April 2020)

• Peru: INS Issues Communications for Clinical Trials Impacted by COVID-19

• SAHPRA Policy on Conduct of Clincial Trials of Health Products During the Current COVID-19 Pandemic

• SAHPRA Revises GCP Training Requirements and Issues Clinic Clinical Trial Application Guidance for Public Health Emergencies (13 April 2020)

• Thailand FDA Issues Guidelines for Clinical Trials During COVID-19 Outbreak (26 May 2020)

• Uganda: UNCST Issues Guidelines for Research during COVID-19 Pandemic (28 August 2020)

• U.S. FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic